Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 129 of 6351
-
New pill aims to help heart patients breathe easier and move more
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Phase 3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Double-Targeting CAR-T cells aim to outsmart lymphoma relapse
Disease control OngoingCAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more e…
Phase 2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gene therapy shows promise for kids with SMA type 2
Disease control CompletedThis was a Phase III multi-center, single dose (1.2 x 10\^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never ambulatory SMA patients 2 to \<18 years of age.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Simple feeding pause could save preemie lives
Prevention Recruiting nowThe WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (\<30 weeks) will reduce the occurrence of Necrotizing Enterocolitis (NEC). Currently both continued feedi…
Sponsor: IWK Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control OngoingThis is an open, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability and preliminary effectiveness of B7-H3-targeting Chimeric Antigen Receptor-T (CAR-T) cell therapy on patients with recurrent glioblastomas. The study also plan to explore the…
Phase 1 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for lung cancer patients who stop responding to targeted drugs
Disease control OngoingA Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor …
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a short burst of radiation plus triple chemotherapy wipe out rectal cancer before surgery?
Cure OngoingThe aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Could two weeks of heart monitoring prevent a second stroke?
Disease control OngoingStroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age. Atrial fibrillation is associated with a manifold increase in the risk for strok…
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill helps smokers kick the habit in major trial
Disease control CompletedThis placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Phase 3 • Sponsor: Achieve Life Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Gene therapy hope for rare brain disease in children
Disease control OngoingOTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal r…
Phase 3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:33 UTC
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThe purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can adding a Blood-Vessel blocker boost chemotherapy for Triple-Negative breast cancer?
Disease control Recruiting nowThis is a prospective, randomized, open-label clinical study. 128 patients with relapsed or metastatic triple-negative breast cancer (TNBC) who had not been systematically treated are going to be enrolled and randomly assigned to 3 groups. Group A: albumin-bound paclitaxel (260mg…
Phase 2 • Sponsor: The First Affiliated Hospital of Bengbu Medical University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vess…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental vaccine combo takes on childhood brain cancer
Disease control Recruiting nowThis is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes fou…
Phase 1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
CAR T-Cell therapy shows promise for Hard-to-Treat multiple myeloma
Disease control CompletedThis study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Living liver donors offer new hope for advanced colon cancer patients
Disease control Recruiting nowThis study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM. Secondary outcomes are graft survival and donor outcomes i…
Sponsor: Azienda Ospedaliero-Universitaria di Modena • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New quadruple immunotherapy attack on childhood cancer
Disease control Recruiting nowThis is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg…
Phase 2 • Sponsor: Hong Kong Children's Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:10 UTC
-
One-Shot gene therapy could free hemophilia b patients from frequent injections
Disease control OngoingThis is a multi-center, Phase 1/2/3, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of BBM-H901 injection in Hemophilia B subjects with ≤2 International unit per deciliter (IU/dl) residual factor IX (FIX) levels. BB…
Phase 2/3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New COVID-19 vaccine shows promise in large trial
Prevention CompletedThe main purpose of this study is to assess the efficacy of S-268019-b for the prevention of COVID-19 in the initial vaccination period prior to crossover in participants without evidence of infection before vaccination as compared to placebo.
Phase 3 • Sponsor: Shionogi • Aim: Prevention
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo aims to halt Alzheimer's in people with genetic mutation
Disease control OngoingTo assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progr…
Phase 2/3 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC